18F-FDG PET与国际预测指标对于经R-CHOP治疗的弥漫大B细胞淋巴瘤疗效的预测效果及发展趋势
Predictive value of 18F-FDG PET and International Prognostic Index for DLBCL patients treated by R-CHOP and the developing trend

R-CHOP联合化疗极大地提高了CD20阳性的弥漫大B细胞淋巴瘤患者的治愈可能。18氟代脱氧葡萄糖-正电子发射计算机断层显像（18F-FDG PET）与国际预测指数（IPI）作为经典的预后评估方式，却因为利妥昔单抗的加入而面临挑战。该文总结了两种预测方式的评价效能与研究进展，PET从传统的视觉评分方式转向定量－半定量参数评估，IPI针对不同年龄及乳酸脱氢酶水平进行了细化分组。在比较了两种预测方式后，建议将两种方式结合，方可更准确地预估病情发展。
： The R-CHOP combined chemotherapy has largely improved the curability of patients with CD 20+ diffuse large B cell lymphoma (DLBCL). As classic methods for predicting the prognosis, now 18F-FDG PET and international prognostic index (IPI) is facing the challenge of rituximab. This paper summarizes the predictive efficiency and research advances of two methods. For PET, the assessment has been changes from traditional vision assessment to quantitative/semi-quantitative parameter assessment. For IPI, ages and LDH levels are refined and grouped. After comparison, it is recommended that two methods should be integrated in order to better predict the development of the disease